OPKO Health Announces Listing in Major Indices on Tel Aviv Stock Exchange

  OPKO Health Announces Listing in Major Indices on Tel Aviv Stock Exchange

Provides Broader Access to Israeli Investors for Shares already listed on NYSE
                       and TASE under Ticker Symbol OPK

Business Wire

MIAMI -- August 28, 2013

OPKO Health, Inc. (NYSE: OPK), a multi-national biopharmaceutical and
diagnostics company, today announced that OPKO's common stock, which began
trading on the Tel-Aviv Stock Exchange ("TASE") on August 21, 2013, will be
included, effective October 6, 2013, in the following major TASE indices: Tel
Aviv 25, Tel Aviv 100, Tel Aviv Composite, Tel Aviv Biomed, and Tel Aviv

“OPKO’s inclusion in these major TASE indices expands our exposure to Israel’s
vibrant investment community and its large and sophisticated investors,”
commented Dr. Phillip Frost, OPKO’s Chairman and Chief Executive Officer. “Our
participation in these major indices conveys broader coverage through
index-based instruments, exchange traded notes, funds and specialized funds,
while providing easier access to institutional and private investors within
the Israeli market."

OPKO will remain subject to the rules and regulations of the NYSE and of the
U.S. Securities and Exchange Commission. Trading on the TASE occurs on Sunday
from 9:45 AM to 4:30 PM Israel time and on Monday through Thursday from 9:45
AM to 5:30 PM Israel time, except on TASE trading holidays. Through the
amendment to Israel's Securities Law 5728-1968, that took effect in October
2000, U.S.-listed companies may dual-list on the TASE without any additional
regulatory requirements. TASE links to the U.S. markets via a direct link to
DTC, a subsidiary of the Depository Trust & Clearing Corporation, which
facilitates the trading of dually-listed securities.


OPKO is a multinational biopharmaceutical and diagnostics company that seeks
to establish industry leading positions in large, rapidly growing markets by
leveraging its discovery, development and commercialization expertise and
novel and proprietary technologies. For more information, visit


This press release includes forward looking statements, within the meaning of
the Private Securities Litigation Reform Act of 1995, which are subject to
risk and uncertainties that could cause actual results to differ materially
from those anticipated. Such statements may relate to OPKO's plans, objectives
and expected financial and operating results, including statements regarding
our ability to expand our exposure to the Israeli investment community and
increase interest in OPKO among Israel's large and sophisticated institutional
investors. The words "may," "could," "would," "will," "believe," "anticipate,"
"estimate," "expect," "intend," "plan," and similar expressions or variations
thereof are intended to identify forward-looking statements. Investors are
cautioned that any such forward-looking statements are not guarantees of
future performance and involve risks and uncertainties, many of which are
beyond OPKO's ability to control. The risks and uncertainties that may affect
forward looking statements include, but are not limited to: currency
fluctuations, global economic and political conditions, marketing demand for
OPKO's products and services, long sales cycles, new product development,
assimilating future acquisitions, maintaining relationships with customers and
partners, and increased competition, as well as the risk we may not complete
the acquisition of PROLOR Biotech, Inc. For more details about the risks and
uncertainties related to OPKO's business, refer to OPKO's filings with the
Securities and Exchange Commission. OPKO undertakes no obligation to publicly
update or revise any forward looking statements, whether as a result of new
information, future events or otherwise.


OPKO Heath, Inc.
Steve D. Rubin, +1-305-575-4100
Executive Vice President — Administration
Juan F. Rodriguez, +1-305-575-4100
Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.